{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:37:00Z","timestamp":1792431420226,"version":"4.5.0"},"reference-count":302,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institute of Nuclear Chemistry and Technology, Warsaw, Poland","award":["This research was funded by statutory activity"],"award-info":[{"award-number":["This research was funded by statutory activity"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Methotrexate, a structural analogue of folic acid, is one of the most effective and extensively used drugs for treating many kinds of cancer or severe and resistant forms of autoimmune diseases. In this paper, we take an overview of the present state of knowledge with regards to complex mechanisms of methotrexate action and its applications as immunosuppressive drug or chemotherapeutic agent in oncological combination therapy. In addition, the issue of the potential benefits of methotrexate in the development of neurological disorders in Alzheimer\u2019s disease or myasthenia gravis will be discussed.<\/jats:p>","DOI":"10.3390\/ijms21103483","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T10:53:59Z","timestamp":1589540039000},"page":"3483","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":316,"title":["Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0471-6949","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Ko\u017ami\u0144ski","sequence":"first","affiliation":[{"name":"Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0657-3793","authenticated-orcid":false,"given":"Pawe\u0142 Krzysztof","family":"Halik","sequence":"additional","affiliation":[{"name":"Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Chesori","sequence":"additional","affiliation":[{"name":"Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7446-1115","authenticated-orcid":false,"given":"Ewa","family":"Gniazdowska","sequence":"additional","affiliation":[{"name":"Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood.V4.2.160.160","article-title":"Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer","volume":"4","author":"Farber","year":"1949","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","article-title":"Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis","volume":"221","author":"Gubner","year":"1951","journal-title":"Am. J. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archderm.1958.01560080060010","article-title":"Treatment of Psoriasis with Folic Acid Antagonists","volume":"78","author":"Edmundson","year":"1958","journal-title":"AMA Arch. Derm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780280702","article-title":"Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"28","author":"Williams","year":"1985","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0002-9343(85)90312-2","article-title":"Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations","volume":"79","author":"Weinstein","year":"1985","journal-title":"Am. J. Med."},{"key":"ref_6","unstructured":"(2020, January 02). Methotrexate Injection, USP, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/011719s125lbl.pdf."},{"key":"ref_7","unstructured":"(2020, January 02). Methotrexate oral solution, FDA Full Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208004s002lbl.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJM197504172921607","article-title":"New Approaches to Cancer Chemotherapy with Methotrexate","volume":"292","author":"Frei","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1056\/NEJM198602203140803","article-title":"Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia","volume":"314","author":"Evans","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/1097-0142(19810315)47:6<1246::AID-CNCR2820470603>3.0.CO;2-G","article-title":"Methotrexate: An Active Drug in Bladder Cancer","volume":"47","author":"Natale","year":"1981","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0065-2571(94)90025-6","article-title":"The methotrexate story: A paradigm for development of cancer chemotherapeutic agents","volume":"34","author":"Huennekens","year":"1994","journal-title":"Advan. Enzym. Regul."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer\u2014The Results of 20 Years of Follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/cncr.20152","article-title":"High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma","volume":"100","author":"Crews","year":"2004","journal-title":"Cancer"},{"key":"ref_14","first-page":"418","article-title":"Methotrexate in rheumatoid arthritis. Health and Public Policy Committee, American College of Physicians","volume":"107","author":"Tugwell","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0190-9622(88)80237-8","article-title":"Methotrexate in psoriasis: Revised guidelines","volume":"19","author":"Roenigk","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CND.0000000000000057","article-title":"Methotrexate treatment in myasthenia gravis","volume":"16","author":"Karaahmet","year":"2014","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_18","first-page":"1730","article-title":"Methotrexate in Crohn\u2019s disease: Long-term efficacy and toxicity","volume":"95","author":"Zenjari","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.410370108","article-title":"Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis","volume":"37","author":"Goodkin","year":"1995","journal-title":"Ann. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"ACEP Clinical Policies Committee and the Clinical Policies Subcommittee on Early Pregnancy (2003). Clinical policy: Critical issues in the initial evaluation and management of patients presenting to the emergency department in early pregnancy. Ann. Emerg. Med., 41, 123\u2013133.","DOI":"10.1067\/mem.2003.13"},{"key":"ref_21","first-page":"iv3","article-title":"Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis","volume":"51","author":"Jacobs","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1535-7163.MCT-06-0343","article-title":"Pemetrexed: Biochemical and cellular pharmacology, mechanisms, and clinical applications","volume":"6","author":"Chattopadhyay","year":"2007","journal-title":"Mol. Cancer. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15764","DOI":"10.1021\/jacs.8b08249","article-title":"Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy","volume":"140","author":"Matera","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Raimondi, M.V., Randazzo, O., La Franca, M., Barone, G., Vignoni, E., Rossi, D., and Collina, S. (2019). DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents. Molecules, 24.","DOI":"10.3390\/molecules24061140"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/bjc.1996.10","article-title":"Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro","volume":"73","author":"Huschtascha","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_27","first-page":"S5","article-title":"Mechanism of Action of Methotrexate","volume":"71","author":"Chan","year":"2013","journal-title":"Bull. Hosp. Jt. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-3109(00)00189-2","article-title":"Mechanisms of action of methotrexate","volume":"47","author":"Genestier","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_29","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular Basis for Pharmacokinetics and Pharmacodynamics of Methotrexate in Rheumatoid Arthritis Treatment","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0083-6729(03)01012-4","article-title":"Membrane transport of folates","volume":"Volume 66","author":"Litwack","year":"2003","journal-title":"Vitamins and Hormones"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.addr.2004.01.010","article-title":"Folate receptor endocytosis and trafficking","volume":"56","author":"Sabharanjak","year":"2004","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1021\/acs.biochem.8b00607","article-title":"Internalization of Methotrexate Conjugates by Folate Receptor-\u03b1","volume":"57","author":"Nogueira","year":"2018","journal-title":"Biochemistry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0006-291X(73)90949-2","article-title":"Polygammaglutamyl metabolites of methotrexate","volume":"52","author":"Baugh","year":"1973","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate: Is methotrexate a prodrug?","volume":"76","author":"Chabner","year":"1985","journal-title":"J. Clin. Invest."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/ph2030077","article-title":"A New Classification of Prodrugs: Regulatory Perspectives","volume":"2","author":"Wu","year":"2009","journal-title":"Pharmaceuticals"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9720","DOI":"10.1016\/S0021-9258(17)39298-0","article-title":"Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates","volume":"260","author":"Allegra","year":"1985","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/bj2360193","article-title":"Inhibition of 5-aminoimidazole4-carboxamide ribotide transformylase, adenosine deaminase and 5\u2019-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide","volume":"236","author":"Baggott","year":"1986","journal-title":"Biochem. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","article-title":"Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates","volume":"82","author":"Allegra","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","first-page":"11038","article-title":"Antifolates Induce Inhibition of Amido Phosphoribosyltransferase in Leukemia","volume":"267","author":"Sant","year":"1992","journal-title":"Cell J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj3420143","article-title":"Methotrexate Inhibits the First Committed Step of Purine Biosynthesis in Mitogen-Stimulated Human T-lymphocytes: A Metabolic Basis for Efficacy in Rheumatoid Arthritis?","volume":"341","author":"Fairbanks","year":"1999","journal-title":"Biochem. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive Properties of Methotrexate: Apoptosis and Clonal Deletion of Activated Peripheral T Cells","volume":"102","author":"Genestier","year":"1998","journal-title":"J. Clin. Invest."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1172\/JCI1554","article-title":"Methotrexate and Sulfasalazine Promote Adenosine Release by a Mechanism that Requires Ecto-59-nucleotidase\u2013mediated Conversion of Adenine Nucleotides","volume":"101","author":"Morabito","year":"1998","journal-title":"J. Clin. Invest."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1476-5381.2010.00667.x","article-title":"Expression and Functional Role of Adenosine Receptors in Regulating Inflammatory Responses in Human Synoviocytes","volume":"160","author":"Varani","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar3871","article-title":"Adenosine receptor expression in rheumatoid synovium: A basis for methotrexate action","volume":"14","author":"Stamp","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Vincenzi, F., Padovan, M., Targa, M., Corciulo, C., Giacuzzo, S., Merighi, S., Gessi, S., Govoni, M., Borea, P.A., and Varani, K. (2013). A2A Adenosine Receptors Are Differentially Modulated by Pharmacological Treatments in Rheumatoid Arthritis Patients and Their Stimulation Ameliorates Adjuvant-Induced Arthritis in Rats. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054195"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1073\/pnas.88.6.2441","article-title":"Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells","volume":"88","author":"Cronstein","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1172\/JCI112638","article-title":"Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells","volume":"78","author":"Cronstein","year":"2001","journal-title":"J. Clin. Invest."},{"key":"ref_51","first-page":"587","article-title":"Effects of methotrexate on leukotriene and derivated lipoxygenase synthesis in polynuclear neutrophils in rheumatoid polyarthritis","volume":"59","author":"Leroux","year":"1992","journal-title":"Rev. Rheum. Mal. Osteoartic."},{"key":"ref_52","first-page":"667","article-title":"Mechanism of action of methotrexate: Experimental evidence that methotrexate blocks the binding of interleukin-1 beta to the interleukin-1 receptor on target cells","volume":"31","author":"Brody","year":"1993","journal-title":"Eur. J. Chem. Clin. Biochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.4049\/jimmunol.153.9.4159","article-title":"Differential regulatory effects of adenosine on cytokine release by activated human monocytes","volume":"153","author":"Bouma","year":"1994","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1998.tb11153.x","article-title":"Activation and methotrexate-mediated suppression of the TNF alpha promoter in T cells and macrophages","volume":"859","author":"Becker","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/1529-0131(199801)41:1<48::AID-ART7>3.0.CO;2-K","article-title":"Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction","volume":"41","author":"Constantin","year":"1998","journal-title":"Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.it.2003.11.003","article-title":"Adenosine: An endogenous regulator of innate immunity","volume":"25","author":"Hasko","year":"2004","journal-title":"Trends Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.1996.270.2.C522","article-title":"Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells","volume":"270","author":"Bouma","year":"1996","journal-title":"Am. J. Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/art.1780330706","article-title":"The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine","volume":"33","author":"Nesher","year":"1990","journal-title":"Arthritis Rheum."},{"key":"ref_59","first-page":"689","article-title":"Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis","volume":"19","author":"Yukioka","year":"1992","journal-title":"J. Rheumatol."},{"key":"ref_60","first-page":"395","article-title":"In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients","volume":"14","author":"Nesher","year":"1996","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_61","first-page":"343","article-title":"Effect of treatment with methotrexate, hydroxychloroquine, and prednisone on lymphocyte polyamine levels in rheumatoid arthritis: Correlation with the clinical response and rheumatoid factor synthesis","volume":"15","author":"Nesher","year":"1997","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3390\/ijms16011772","article-title":"Mechanisms and Implications of Dual-Acting Methotrexate in Folate-Targeted Nanotherapeutic Delivery","volume":"16","author":"Wong","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1158\/1078-0432.CCR-03-0157","article-title":"The Role of \u03b1-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs","volume":"10","author":"Theti","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Kerschbaumer, A., Sepriano, A., Smolen, J.S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I.B., Bijlsma, J.W.J., Burmester, G.R., and de Wit, M. (2020). Efficacy of pharmacological treatment in rheumatoid arthritis: A systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann. Rheum. Dis., 1\u201315.","DOI":"10.1136\/annrheumdis-2019-216656"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: Recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1517\/14656566.2012.705831","article-title":"Treatment strategies for myasthenia gravis: An update","volume":"13","author":"Illa","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/BOR.0b013e328333ba74","article-title":"Rheumatic manifestations of systemic disease: Sarcoidosis","volume":"22","author":"Chantam","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/thx.54.8.742","article-title":"A clinical approach to the use of methotrexate for sarcoidosis","volume":"54","author":"Baughman","year":"1999","journal-title":"Thorax"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive Methotrexate for Treatment of Giant Cell Arteritis. An Individual Patient Data Meta-Analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12969-018-0255-8","article-title":"Methotrexate in juvenile idiopathic arthritis: Advice and recommendations from the MARAJIA expert consensus meeting","volume":"16","author":"Ferrara","year":"2018","journal-title":"Pediatr. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/187152811304140915152102","article-title":"An update on Disease Modifying Antirheumatic drugs","volume":"13","author":"Joshi","year":"2014","journal-title":"Inflamm. Allergy Drug Target"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/WCO.0b013e3283572588","article-title":"Myasthenia and the neuromuscular junction","volume":"25","author":"Gilhus","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","volume":"129","author":"Andersen","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/ene.13788","article-title":"Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence","volume":"25","author":"Gilhus","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ncpneuro0810","article-title":"Steroids and immunosuppressant drugs in myasthenia gravis","volume":"4","author":"Sathasivam","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1468-1331.2008.02176.x","article-title":"MuSK-positive myasthenia gravis is rare in the Polish population","volume":"15","author":"Dutkiewicz","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"116648","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1756285608093888","article-title":"Progress in the treatment of myasthenia gravis","volume":"1","author":"Gold","year":"2008","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/TCRM.S14015","article-title":"Current and emerging treatments for the management of myasthenia gravis","volume":"7","author":"Sathasivam","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"E84","DOI":"10.1055\/s-0043-124983","article-title":"Treatment Standards and Individualized Therapy of Myasthenia Gravis","volume":"2","author":"Urban","year":"2018","journal-title":"Neurol. Int. Open"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: An update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clinph.2008.10.138","article-title":"Methotrexate in myasthenia gravis","volume":"120","author":"Hartmann","year":"2009","journal-title":"Clin. Neurophysiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.nurt.2008.08.011","article-title":"Current and future standards in treatment of myasthenia gravis","volume":"5","author":"Gold","year":"2008","journal-title":"Neurotherapeutics"},{"key":"ref_88","first-page":"300","article-title":"Methotrexate for treatment of myasthenia gravis","volume":"62","author":"Abdou","year":"2007","journal-title":"Neurology"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Heckmann, J.M., Rawoot, A., Bateman, K., Renison, R., and Badri, M. (2011). A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol., 11.","DOI":"10.1186\/1471-2377-11-97"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"Methotrexate in MG Investigators of the Muscle Study Group. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","article-title":"Epidemiology of adult rheumatoid arthritis","volume":"4","author":"Alamanos","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2018.07.014","article-title":"Molecular mechanisms of autophagic memory in pathogenic T cells in human arthritis","volume":"94","author":"Kumar","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3389\/fimmu.2015.00384","article-title":"T Cell Migration in Rheumatoid Arthritis","volume":"6","author":"Mellado","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000060522","article-title":"The role of TNF alpha and IL-1 in rheumatoid arthritis","volume":"3","author":"Feldmann","year":"2001","journal-title":"Curr. Dir. Autoimmun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18053\/jctres.02.201603.005","article-title":"The role of TNF-\u03b1 in rheumatoid arthritis: A focus on regulatory T cells","volume":"2","author":"Farrugia","year":"2016","journal-title":"J. Clin. Transl. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1038\/s41598-020-60314-w","article-title":"T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum: Implications for management","volume":"10","author":"Ponchel","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_99","first-page":"313","article-title":"Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis","volume":"16","author":"Furst","year":"1989","journal-title":"J. Rheumatol."},{"key":"ref_100","first-page":"16","article-title":"Methotrexate in rheumatoid arthritis: A quarter century of development","volume":"124","author":"Weinblatt","year":"2013","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"i1777","DOI":"10.1136\/bmj.i1777","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: Abridged Cochrane systematic review and network meta-analysis","volume":"353","author":"Hazlewood","year":"2016","journal-title":"BMJ"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/0140-6736(90)91101-F","article-title":"Anti-inflammatory drugs and Alzheimer disease","volume":"335","author":"McGeer","year":"1990","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.trci.2017.10.002","article-title":"Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients","volume":"3","author":"Judge","year":"2017","journal-title":"Alzheimers Dement."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Zhou, M., Xu, R., Kaelber, D.C., and Gurney, M.E. (2020). Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer\u2019s disease in patients with rheumatoid arthritis and psoriasis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229819"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s40263-016-0374-z","article-title":"Treatment for Rheumatoid Arthritis and Risk of Alzheimer\u2019s Disease: A Nested Case-Control Analysis","volume":"30","author":"Chou","year":"2016","journal-title":"CNS Drugs"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1468-3083.2000.00058.x","article-title":"Methotrexate in psoriasis: 26 years\u2019 experience with low-dose long-term treatment","volume":"14","author":"Haustein","year":"2000","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-0960.2011.00839.x","article-title":"The use of methotrexate in dermatology: A review","volume":"53","author":"Shen","year":"2012","journal-title":"Australas. J. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-86-2-199","article-title":"Methotrexate","volume":"86","author":"Weinstein","year":"1977","journal-title":"Ann. Intern. Med."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Busger op Vollenbroek, F.T.M., Doggen, C.J.M., Janssens, R.W.A., and Bernelot Moens, H.J. (2018). Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194401"},{"key":"ref_111","first-page":"655","article-title":"Skin directed therapy for mycosis fungoides: A review","volume":"7","author":"Berthelot","year":"2008","journal-title":"J. Drugs Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1111\/j.1468-3083.2012.04654.x","article-title":"Methotrexate for treatment of lichen planus: Old drug, new indication","volume":"27","author":"Kanwar","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_113","first-page":"607","article-title":"Concepts and controversies in the treatment of cutaneous lichen planus","volume":"152","author":"Puza","year":"2017","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.rmed.2009.12.009","article-title":"Pharmacotherapy for pulmonary sarcoidosis: A Delphi consensus study","volume":"104","author":"Schutt","year":"2010","journal-title":"Respir. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1164\/rccm.201006-0865CI","article-title":"A concise review of pulmonary sarcoidosis","volume":"183","author":"Baughman","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_116","first-page":"518","article-title":"Methotrexate as a single agent for treating pulmonary sarcoidosis: A single centre real-life prospective study","volume":"82","author":"Bednarek","year":"2014","journal-title":"Pneumonol. Alergol. Pol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease","volume":"332","author":"Feagan","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease","volume":"342","author":"Feagan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.51.10.1249","article-title":"The 150th anniversary of the first depiction of the lesions of multiple sclerosis","volume":"51","author":"Compston","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.58.2.314","article-title":"An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS","volume":"58","author":"Calabresi","year":"2002","journal-title":"Neurology"},{"key":"ref_122","first-page":"457","article-title":"Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon \u03b2-1\u03b1: A randomized controlled trial","volume":"16","author":"Ashtari","year":"2011","journal-title":"J. Res. Med. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286419892360","article-title":"Safety of long-term intrathecal methotrexate in progersive forms of MS","volume":"12","author":"Stark","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_124","unstructured":"Swerdlow, S.H. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, International Agency for Research on Cancer. [4th ed.]. (updated in 2016)."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2399","article-title":"The 2016 updated WHO classification of lymphoid neoplasias","volume":"35","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/17425247.2012.642362","article-title":"Methotrexate: A detailed review on drug delivery and clinical aspects","volume":"9","author":"Khan","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_127","first-page":"373","article-title":"Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples","volume":"9","author":"Karami","year":"2019","journal-title":"J. Pharm."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1592\/phco.25.5.748.63584","article-title":"High-Dose Methotrexate in Acute Lymphoblastic Leukemia: Where Is the Evidence for Its Continued Use?","volume":"25","author":"Mantadakis","year":"2005","journal-title":"Pharmacotherapy"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archderm.1997.03890430121016","article-title":"Lymphomas during Long-term Methotrexate Therapy","volume":"133","author":"Kamel","year":"1997","journal-title":"Arch. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archderm.1997.03890430083011","article-title":"Epstein-Barr Virus-Associated Lymphoproliferative Disease During Methotrexate Therapy for Psoriasis","volume":"133","author":"Paul","year":"1997","journal-title":"Arch. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/cco.2019.01.02","article-title":"Systemic therapy of cutaneous T-cell lymphoma (CTCL)","volume":"8","author":"Alpdogan","year":"2019","journal-title":"Chin. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: A retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and S\u00e8zary syndrome","volume":"127","author":"Whittaker","year":"2016","journal-title":"Blood"},{"key":"ref_134","first-page":"3586","article-title":"Methotrexate in the treatment of mycosis fungoides-a multicenter observational study in 79 patients","volume":"22","author":"Maj","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/annonc\/mdz388","article-title":"Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): An open-label, randomised phase III trial","volume":"30","author":"Guo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/0976-500X.136098","article-title":"Metronomic chemotherapy","volume":"5","author":"Maiti","year":"2014","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Wen, J., Ma, X., Ruan, D., Chen, J., Lin, Q., Dong, M., Li, H., and Wu, H. (2014). The efficacy of metronomic thalimomide and methotrexate for refractory\/relapsed non-Hodgkin lymphoma. J. Clin. Oncol., 32.","DOI":"10.1200\/jco.2014.32.15_suppl.e19508"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/1097-0142(197305)31:5<1141::AID-CNCR2820310515>3.0.CO;2-R","article-title":"Chemotherapy of cancer of the head and neck","volume":"31","author":"Bertino","year":"1973","journal-title":"Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S1726-4901(08)70135-7","article-title":"Methotrexate and Leucovorin Double-Modulated 5-fluorouracil Combined With Cisplatin (MPFL) in Metastatic\/Recurrent Head and Neck Cancer","volume":"71","author":"Chang","year":"2008","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4161\/15384047.2014.961881","article-title":"Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma","volume":"16","author":"Kushwaha","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0019-509X.117024","article-title":"Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis","volume":"50","author":"Pai","year":"2013","journal-title":"Indian J. Cancer"},{"key":"ref_142","first-page":"203","article-title":"Outcome of Oral Metronomic Therapy with Methotrexate and Celecoxib in Advanced\/Recurrent Head and Neck Squamous Cell Carcinoma","volume":"6","author":"Kumar","year":"2019","journal-title":"Int. J. Sci. Study"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e17007","DOI":"10.1200\/jco.2015.33.15_suppl.e17007","article-title":"Metronomic chemotherapy in recurrent head and neck cancer","volume":"33","author":"Mateen","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/CMAR.S138661","article-title":"Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): Focus on chlormethine gel","volume":"20","author":"Denis","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1179\/1607845415Y.0000000002","article-title":"Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory\/relapsed cutaneous T-cell lymphoma","volume":"20","author":"Aviles","year":"2015","journal-title":"Hematology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.det.2015.05.009","article-title":"Methotrexate and Pralatrexate","volume":"33","author":"Wood","year":"2015","journal-title":"Dermatol. Clin."},{"key":"ref_147","first-page":"836","article-title":"Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides\/S\u00e9zary syndrome","volume":"22","author":"Aviles","year":"2007","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.dsi.2015.07.009","article-title":"Erythrodermic mycosis fungoides treated with low-dose methotrexate and 311 nm UV-B: A case report with 3-year follow up and literature review","volume":"34","author":"Kuo","year":"2016","journal-title":"Dermatol. Sin."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/ijd.IJD_71_17","article-title":"Management strategies for mycosis fungoides in India","volume":"62","author":"Raychaudhury","year":"2017","journal-title":"Indian J. Dermatol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/1097-0142(19861215)58:12<2611::AID-CNCR2820581210>3.0.CO;2-W","article-title":"Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM-M)","volume":"58","author":"Zakem","year":"1986","journal-title":"Cancer"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1097-0142(19810115)47:2<229::AID-CNCR2820470204>3.0.CO;2-P","article-title":"Progress in the Chemotherapy of Small Cell. Carcinoma of the Lung","volume":"47","author":"Vincent","year":"1981","journal-title":"Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0002-9343(82)90745-8","article-title":"Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancer","volume":"73","author":"Hande","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_153","first-page":"1056","article-title":"High-dose methotrexate in small cell lung cancer","volume":"51","author":"Neijstrom","year":"1983","journal-title":"Lack of efficacy in preventing CNS relapse. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00614550","article-title":"Effect of methotrexate on the pharmacokinetics and renal excretion of cisplatin","volume":"34","author":"Preiss","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_155","first-page":"123","article-title":"Methotrexate (MTX), mitomycin C (MMC), vinorelbine (M) and cisplatinum (P) [M-MNP] in the treatment of advanced non-small cell lung cancer (NSCLC)","volume":"11","author":"Malzyner","year":"1994","journal-title":"Lung Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1464-410X.1974.tb10181.x","article-title":"Methotrexate Treatment for Advanced Bladder Cancer","volume":"46","author":"Hall","year":"1974","journal-title":"Br. J. Urol."},{"key":"ref_157","first-page":"471","article-title":"Phase II study of methotrexate (NSC-740) in solid tumors","volume":"51","author":"Andrews","year":"1976","journal-title":"Cancer Chemother. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.1977.tb04551.x","article-title":"The Treatment of Advanced Bladder Cancer with Methotrexate","volume":"49","author":"Turner","year":"1977","journal-title":"Br. J. Urol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0277-5379(84)90191-3","article-title":"The treatment of advanced bladder cancer with methotrexate and cisplatinum\u2014A pharmacokinetic study","volume":"20","author":"Kaye","year":"1984","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1007\/BF00262483","article-title":"The chemotherapy of advanced bladder cancer","volume":"20","author":"Newling","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1756-8722-4-35","article-title":"Chemotherapy in advanced bladder cancer: Current status and future","volume":"4","author":"Ismaili","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000030493","article-title":"Second-Line Chemotherapy in Advanced Bladder Cancer","volume":"64","author":"Sternberg","year":"2000","journal-title":"Urol. Int."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0022-5347(17)49106-3","article-title":"Vinblastine and methotrexate for advanced bladder cancer","volume":"133","author":"Ahmed","year":"1985","journal-title":"J. Urol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bjc.6603273","article-title":"Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells","volume":"95","author":"Sinha","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.17925\/EOH.2017.13.02.134","article-title":"Systemic Chemotherapy for Urothelial Cancer\u2013How to Select Systemic Therapy in Bladder Cancer","volume":"13","author":"Dimitriadis","year":"2017","journal-title":"Eur. Oncol. Haematol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/leu.2017.283","article-title":"High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG","volume":"32","author":"Sakura","year":"2018","journal-title":"Leukemia"},{"key":"ref_167","first-page":"25","article-title":"Neurocognitive late effects of chemotherapy in survivors of acute lymphoblastic leukemia: Focus on methotrexate","volume":"24","author":"Nieman","year":"2015","journal-title":"J. Can. Acad. Child. Adolesc. Psychiatry"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1172\/JCI106181","article-title":"Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates","volume":"48","author":"Hryniuk","year":"1969","journal-title":"J. Clin. Investig."},{"key":"ref_169","unstructured":"Brenner, T.L., and Evans, W.E. (2003). Rationale for High-Dose Methotrexate in Childhood Acute Lymphoblastic Leukemia. Treatment of Acute Leukemias, Antileukemic Drugs, Humana Press."},{"key":"ref_170","unstructured":"Camitta, B.M., and Kamen, B.A. (2003). Role of Methotrexate in the Treatment of Acute Lymphoblastic Leukemia. Treatment of Acute Leukemias: Antileukemic Drugs, Humana Press."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/030089168507100211","article-title":"High-dose methotrexate-leucovorin rescue therapy: Selected application in non-Hodgkin\u2019s lymphoma","volume":"71","author":"Rizzoli","year":"1985","journal-title":"Tumori"},{"key":"ref_172","first-page":"125","article-title":"Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin\u2019s lymphoma of unfavorable histology","volume":"65","author":"Canellos","year":"1981","journal-title":"Cancer Treat. Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1016077907952","article-title":"Is Intrathecal Methotrexate Necessary in the Treatment of Primary CNS Lymphoma?","volume":"58","author":"Khan","year":"2002","journal-title":"J. Neurooncol."},{"key":"ref_174","first-page":"711","article-title":"High-Dose Methotrexate for Intraocular Lymphoma","volume":"9","author":"Batchelor","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01376517-200704000-00004","article-title":"High-Dose Methotrexate and Primary Central Nervous System Lymphoma","volume":"39","author":"Fahey","year":"2007","journal-title":"J. Neurosci. Nurs."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1215\/15228517-2008-067","article-title":"High-dose methotrexate for elderly patients with primary CNS lymphoma","volume":"11","author":"Zhu","year":"2009","journal-title":"Neuro-Oncology"},{"key":"ref_177","first-page":"4423","article-title":"Efficacy and association analysis of high-dose methotrexate in the treatment of children with acute lymphoblastic leukemia","volume":"17","author":"Gong","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_178","first-page":"69","article-title":"BHS guidelines for primary central nervous system lymphoma","volume":"7","author":"Dierickx","year":"2016","journal-title":"Belg. J. Hematol."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Bergner, N., Monsef, I., Illerhaus, G., Engert, A., and Skoetz, N. (2012). Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database Syst. Rev., 11.","DOI":"10.1002\/14651858.CD009355.pub2"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/10428190290012092","article-title":"Central Nervous System Relapse of Systemic Non-Hodgkin\u2019s Lymphoma: Results of Treatment Based on High-dose Methotrexate Combination Chemotherapy","volume":"43","author":"Bokstein","year":"2002","journal-title":"Leuk. Lymphoma"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-007-9397-0","article-title":"Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly","volume":"85","author":"Omuro","year":"2007","journal-title":"J. Neurooncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"49156","DOI":"10.18632\/oncotarget.17101","article-title":"Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1182\/blood.V122.21.5108.5108","article-title":"High-Dose Methotrexate in the Treatment of Primary Testicular Lymphoma","volume":"122","author":"Reinius","year":"2013","journal-title":"Blood"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1182\/blood.V124.21.3090.3090","article-title":"Rituximab with High Dose Methotrexate in the Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma","volume":"124","author":"Kansara","year":"2014","journal-title":"Blood"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.3892\/ol.2016.4393","article-title":"Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience","volume":"11","author":"Inaly","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_187","unstructured":"(2020, January 02). BC Cancer Protocol Summary LYHDMRP. BC Cancer Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and rituximab. Available online: http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Lymphoma-Myeloma\/LYHDMRP_Protocol.pdf."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/1097-0142(197903)43:3<1095::AID-CNCR2820430347>3.0.CO;2-P","article-title":"High dose methotrexate with and without BCG therapy in advanced head and neck malignancy","volume":"43","author":"Buechler","year":"1979","journal-title":"Cancer"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archderm.1995.01690150071014","article-title":"Treatment of Advanced Mycosis Fungoides and S\u00e9zary Syndrome with Continuous Infusions of Methotrexate Followed by Fluorouracil and Leucovorin Rescue","volume":"131","author":"Schappell","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00044-014-1172-0","article-title":"Development of reversible glutamine conjugate of methotrexate for enhanced brain delivery","volume":"24","author":"Singh","year":"2015","journal-title":"Med. Chem. Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3109\/10717544.2014.984369","article-title":"Development and characterization of lysine-methotrexate conjugate for enhanced brain delivery","volume":"23","author":"Singh","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_192","first-page":"1595","article-title":"Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles","volume":"6","author":"Ram","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4155\/tde.12.55","article-title":"Polymeric nanocarriers for controlled and enhanced delivery of therapeutic agents to the CNS","volume":"3","author":"Gagliardi","year":"2012","journal-title":"Ther. Deliv."},{"key":"ref_194","first-page":"1917","article-title":"Vivo Antitumor Activity of Methotrexate Conjugated to Human Serum Albumin in Human Cancer Cells","volume":"9","author":"Wosikowski","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/1097-0215(20010601)92:5<718::AID-IJC1257>3.0.CO;2-D","article-title":"Pre-clinical Evaluation of a Methotrexate-Albumin Conjugate (MTX-HSA) in Human Tumor Xenografts in Vivo","volume":"92","author":"Burger","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1021\/la0503451","article-title":"Methotrexate-Modified Superparamagnetic Nanoparticles and Their Intracellular Uptake into Human Cancer Cells","volume":"21","author":"Kohler","year":"2005","journal-title":"Langmuir"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2005.11.040","article-title":"Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles","volume":"310","author":"Gao","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1208\/s12249-011-9695-x","article-title":"Methotrexate-loaded chitosan- and glycol chitosan-based nanoparticles: A promising strategy for the administration of the anticancer drug to brain tumors","volume":"12","author":"Trapani","year":"2011","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11095-014-1545-6","article-title":"Nanoparticles and the Blood-Brain Barrier: Advancing from In-Vitro Models towards Therapeutic Significance","volume":"32","author":"Malhotra","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0378-5173(00)00476-2","article-title":"Characterization and in Vitro Release of Methotrexate From Gelatin\/Methotrexate Conjugates Formed Using Different Preparation Variables","volume":"204","author":"Kosasih","year":"2000","journal-title":"Int. J. Pharm."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/02652049409040439","article-title":"Controlled release of anticancer drug methotrexate from biodegradable gelatin microspheres","volume":"11","author":"Narayani","year":"1994","journal-title":"J. Microencapsul."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0378-5173(95)04323-3","article-title":"Biodegradable microspheres using two different gelatin drug conjugates for the controlled delivery of methotrexate","volume":"128","author":"Narayani","year":"1996","journal-title":"Int. J. Pharm."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/jps.20572","article-title":"Gelatin\u2013methotrexate conjugate microspheres as a potential drug delivery system","volume":"95","author":"Pica","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijpharm.2005.10.037","article-title":"Growth inhibition, drug load, and degradation studies of gelatin\/methotrexate conjugates","volume":"308","author":"Ofner","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijpharm.2019.01.024","article-title":"Controlled release of methotrexate from functionalized silica-gelatin aerogel microparticles applied against tumor cell growth","volume":"558","author":"Nagy","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1158\/0008-5472.CAN-04-3921","article-title":"Nanoparticle Targeting of Anticancer Drug Improves Therapeutic Response in Animal Model of Human Epithelial Cancer","volume":"65","author":"Candido","year":"2005","journal-title":"Cancer Res."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1021\/bm0506142","article-title":"PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality","volume":"7","author":"Majoros","year":"2006","journal-title":"Biomacromolecules"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1535-7163.MCT-05-0325","article-title":"Targeted delivery of methotrexate to epidermal growth factor receptor\u2013positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates","volume":"5","author":"Wu","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1515\/ntrev-2011-0010","article-title":"Nanomedicine: Pharmacological perspectives","volume":"1","author":"Bhattacharya","year":"2012","journal-title":"Nanotechnol. Rev."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.biomaterials.2007.03.012","article-title":"Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate","volume":"28","author":"Dhanikula","year":"2007","journal-title":"Biomaterials"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/bc010098m","article-title":"Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: Synthesis, characterization, and structure-activity relationships in vitro and in vivo","volume":"13","author":"Riebeseel","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"ref_212","first-page":"618","article-title":"Methotrexate and epirubicin conjugates as potential antitumor drugs","volume":"71","author":"Kmiecik","year":"2017","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_213","first-page":"83","article-title":"Preliminary results. UFT\/Methotrexate\/Leucovorin for Breast Cancer Patients in Progression after HDCT\/PBPC Support","volume":"11","author":"Martin","year":"1997","journal-title":"Oncology (Williston Park)"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00000421-200012000-00019","article-title":"Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: A phase II study","volume":"23","author":"Martin","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1019607924403","article-title":"Pathologic Changes Related to CMF Primary Chemotherapy in Breast Cancer","volume":"75","author":"Moreno","year":"2002","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/annonc\/mdi278","article-title":"Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: Short-term responses translated into long-term outcomes","volume":"16","author":"Cocconi","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10549-013-2806-5","article-title":"Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience","volume":"143","author":"Leone","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/s40064-015-1159-4","article-title":"Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine","volume":"4","author":"Fukuda","year":"2015","journal-title":"Springerplus"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/aps.2013.16","article-title":"Methotrexate and 5-aminoimidazole-4-carboxamide riboside exert synergistic anticancer action against human breast cancer and hepatocellular carcinoma","volume":"34","author":"Cheng","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3892\/or.2017.5439","article-title":"Combined treatment with vitamin C and methotrexate inhibits triple-negative breast cancer cell growth by increasing H2O2 accumulation and activating caspase-3 and p38 pathways","volume":"37","author":"Wu","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF00254256","article-title":"Combination Chemotherapy (High-Dose Methotrexate with Citrovorum Factor Rescue, Mechlorethamine, and Procarbazine) in Non-Small Cell Lung Cancer","volume":"11","author":"Bhasin","year":"1983","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1080\/10717544.2018.1477856","article-title":"Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy","volume":"25","author":"Chen","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"e00460","DOI":"10.1002\/prp2.460","article-title":"Combined antitumoral effects of pretubulysin and methotrexate","volume":"7","author":"Kern","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3892\/or.2013.2561","article-title":"Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells","volume":"30","author":"Yan","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejps.2019.03.016","article-title":"Exploiting gelatin nanocarriers in the pulmonary delivery of methotrexate for lung cancer therapy","volume":"133","author":"Abdelrady","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_227","first-page":"1167","article-title":"Vincristine, bleomycin, cyclophosphamide, mitomycin, and methotrexate","volume":"68","author":"Kubota","year":"1984","journal-title":"Cancer Treat. Rep."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1464-410X.1984.tb06142.x","article-title":"Treatment of invasive bladder cancer by local resection and high dose Methotrexate","volume":"56","author":"Hall","year":"1984","journal-title":"Br. J. Urol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1200\/JCO.2007.14.7793","article-title":"High-Dose Methotrexate in Osteosarcoma: Let the Questions Surcease\u2014Time for Final Acceptance","volume":"26","author":"Jaffe","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","article-title":"Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial","volume":"33","author":"Bielack","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mpo.2950150205","article-title":"A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: A report from the Childrens Cancer Study Group","volume":"15","author":"Krailo","year":"1987","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2005.06.031","article-title":"Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and\/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate","volume":"23","author":"Meyers","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.1988.6.2.329","article-title":"Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response","volume":"6","author":"Winkler","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1002\/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C","article-title":"Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin","volume":"72","author":"Bacci","year":"1993","journal-title":"Cancer"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1200\/JCO.2000.18.24.4016","article-title":"Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli\/osteosarcoma-2 protocol: An updated report","volume":"18","author":"Bacci","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_236","first-page":"705","article-title":"Osteosarcoma: A Review of Diagnosis, Management, and Treatment Strategies","volume":"8","author":"Geller","year":"2010","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ygyno.2007.09.006","article-title":"Treatment for Low-Risk Gestational Trophoblastic Disease: Comparison of Single-Agent Methotrexate, Dactinomycin and Combination Regimens","volume":"108","author":"Tiezzi","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2012.06.014","article-title":"Treatment of high-risk gestational trophoblastic neoplasia with weekly high-dose methotrexate-etoposide","volume":"127","author":"Han","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_239","unstructured":"Nebraska Lymphoma Study Group (2020, January 02). Treatment of Non-Hodgkin\u2019s Lymphoma and Hodgkin\u2019s Lymphoma. Available online: https:\/\/www.unmc.edu\/media\/lymphoma\/ne_lymphoma_book.pdf."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"160232","DOI":"10.1098\/rsob.160232","article-title":"Challenging perspectives on the cellular origins of lymphoma","volume":"6","author":"Malcolm","year":"2016","journal-title":"Open Biol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2009.08006.x","article-title":"Paediatric lymphoblastic T-cell leukaemia and lymphoma: One or two diseases?","volume":"149","author":"Burkhardt","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_242","unstructured":"Davis, T.P., Enna, S.J., and Lecount, L. (2014). Pharmacology of the Blood Brain Barrier: Targeting CNS Disorders, Elsevier INC. [1st ed.]."},{"key":"ref_243","first-page":"5631","article-title":"Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment","volume":"35","author":"Cho","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.hemonc.2019.08.008","article-title":"High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature","volume":"12","author":"Kapke","year":"2019","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification","volume":"1","author":"Kasim","year":"2004","journal-title":"Mol. Pharm."},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Torchilin, V.P. (2008). Multifunctional Pharmaceutical Nanocarriers, Springer. [1st ed.].","DOI":"10.1007\/978-0-387-76554-9"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.2174\/092986711798184262","article-title":"Nanostructures for Drug Delivery to the Brain","volume":"18","author":"Holgado","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2174\/092986706777452461","article-title":"Delivering drugs to the central nervous system: A medicinal chemistry or a pharmaceutical technology issue?","volume":"13","author":"Ricci","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Jang, J.H., Jeong, S.H., and Lee, Y.B. (2019). Preparation and In Vitro\/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133312"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/1097-0142(196805)21:5<828::AID-CNCR2820210507>3.0.CO;2-Q","article-title":"Treatment of carcinoma of head and neck with intravenous methotrexate","volume":"21","author":"Leone","year":"1968","journal-title":"Cancer"},{"key":"ref_251","first-page":"1782","article-title":"Methotrexate Therapy of Head and Neck Cancer: Improvement in Therapeutic Index by the Use of Leucovorin \u201cRescue\u201d","volume":"30","author":"Capizzi","year":"1970","journal-title":"Cancer Res."},{"key":"ref_252","first-page":"848","article-title":"Sequential treatment of advanced oral carcinoma by methotrexate and radiotherapy","volume":"61","author":"Pant","year":"1973","journal-title":"Indian J. Med. Res."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/0002-9343(80)90105-9","article-title":"High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity","volume":"68","author":"Frei","year":"1980","journal-title":"Am. J. Med."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.282.6264.600","article-title":"Methotrexate treatment of squamous-cell head and neck cancers: Dose-response evaluation","volume":"282","author":"Woods","year":"1981","journal-title":"Br. Med. J. (Clin. Res. Ed)."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/1097-0142(19810901)48:5<1061::AID-CNCR2820480502>3.0.CO;2-X","article-title":"A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer","volume":"48","author":"DeConti","year":"1981","journal-title":"Cancer"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/1097-0142(19830715)52:2<206::AID-CNCR2820520204>3.0.CO;2-J","article-title":"A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck","volume":"52","author":"Hong","year":"1983","journal-title":"Cancer"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/1097-0142(19830801)52:3<399::AID-CNCR2820520303>3.0.CO;2-1","article-title":"A randomized trial of the combination of cis-platinum, oncovin and bleomycin (COB) versus methotrexate in patients with advanced squamous cell carcinoma of the head and neck","volume":"52","author":"Drelichman","year":"1983","journal-title":"Cancer"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF02994573","article-title":"Single agent methotrexate chemotherapy for head and neck cancers","volume":"43","author":"Pradhan","year":"1991","journal-title":"Indian J. Otolaryngol"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/annonc\/mdq453","article-title":"Optimal treatment for recurrent\/metastatic head and neck cancer","volume":"21","author":"Vermorken","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.1200\/jco.2006.24.18_suppl.15539","article-title":"Weekly methotrexate in squamous cell cancers of head and neck","volume":"24","author":"Pathak","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_261","first-page":"9","article-title":"Methotrexate Revisited\u2014in Recurrent Head and Neck Cancer","volume":"5","author":"Banipal","year":"2011","journal-title":"Palliat. Care Res. Treat."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/2278-330X.142990","article-title":"Methotrexate, an attractive agent for palliation in head and neck cancers","volume":"3","author":"Sharma","year":"2014","journal-title":"South Asian J. Cancer"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(01)00587-3","article-title":"Metronomic scheduling: The future of chemotherapy?","volume":"2","author":"Gasparini","year":"2001","journal-title":"Lancet Oncol."},{"key":"ref_264","doi-asserted-by":"crossref","unstructured":"De Felice, F., Musio, D., and Tombolini, V. (2015). Head and neck cancer: Metronomic chemotherapy. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1705-z"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/jco.2014.32.15_suppl.1079","article-title":"High-dose methotrexate for metastatic breast cancer to the central nervous system: A single-institution review of 46 patients","volume":"32","author":"Schwartz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.2009.25.9549","article-title":"Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: Results from two randomized trials of adjuvant chemoendocrine therapy for nodenegative breast cancer","volume":"28","author":"Colleoni","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_267","first-page":"1301","article-title":"Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy","volume":"34","author":"Wu","year":"2014","journal-title":"Anticancer. Res."},{"key":"ref_268","first-page":"104","article-title":"Breast Cancer in Patients of Rheumatoid Arthritis with Methotrexate Therapy Mimicking Histopathological Changes after Neoadjuvant Chemotherapy","volume":"42","author":"Kumaki","year":"2017","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11739-019-02045-z","article-title":"Assessing the lung cancer risk reduction potential of candidate modified risk tobacco products","volume":"14","author":"Hoeng","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10585-005-5377-y","article-title":"Low-dose Methotrexate Inhibits Lung Metastasis and Lengthens Survival in Rat Osteosarcoma","volume":"22","author":"Tomoda","year":"2005","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijscr.2019.05.033","article-title":"Lung cancer combined with methotrexate-associated lymphoproliferative disorder: A case report","volume":"59","author":"Sekimura","year":"2019","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_272","first-page":"2771","article-title":"The Chemotherapy of Advanced Bladder Carcinoma","volume":"37","author":"deKernion","year":"1977","journal-title":"Cancer Res."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.21873\/anticanres.10982","article-title":"Osteogenic Sarcoma: A 21st Century Review","volume":"36","author":"Osasan","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.3747\/co.21.1973","article-title":"Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy","volume":"21","author":"Xu","year":"2014","journal-title":"Curr. Oncol."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cam4.1898","article-title":"Safety and Efficacy of High-Dose Methotrexate for Osteosarcoma in Adolescents Compared With Young Adults","volume":"8","author":"Wippel","year":"2019","journal-title":"Cancer Med."},{"key":"ref_276","first-page":"621","article-title":"Mechanisms of methotrexate resistance in osteosarcoma","volume":"5","author":"Guo","year":"1999","journal-title":"Clin. Cancer. Res."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3892\/ol.2014.2773","article-title":"Mechanisms of methotrexate resistance in osteosarcoma cell lines and strategies for overcoming this resistance","volume":"9","author":"Wang","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.12659\/MSM.911972","article-title":"miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma","volume":"24","author":"Xu","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"359739","DOI":"10.1155\/2012\/359739","article-title":"MicroRNA involvement in osteosarcoma","volume":"2012","author":"Kobayashi","year":"2012","journal-title":"Sarcoma"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0002-9378(95)90575-8","article-title":"Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors","volume":"172","author":"Lurain","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ygyno.2012.03.039","article-title":"Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: Factors associated with resistance to single-agent methotrexate chemotherapy","volume":"125","author":"Hoekstra","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"80.e1","DOI":"10.1016\/j.ajog.2016.01.183","article-title":"Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone","volume":"215","author":"Couder","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_283","first-page":"CD007102","article-title":"First-line chemotherapy in low-risk gestational trophoblastic neoplasia","volume":"2016","author":"Lawrie","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_284","first-page":"12","article-title":"Current Chemotherapeutic Management of Patients with Gestational Trophoblastic Neoplasia","volume":"2011","author":"May","year":"2011","journal-title":"Chemother. Res. Pract."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"123","DOI":"10.30699\/jogcr.3.3.123","article-title":"New Management of Gestational trophoblastic diseases; A Continuum of Moles to Choriocarcinoma: A Review Article","volume":"3","author":"Aminimoghaddam","year":"2018","journal-title":"J. Obstet. Gynecol. Cancer Res."},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Alazzam, M., Tidy, J., Osborne, R., Coleman, R., Hancock, B.W., and Lawrie, T.A. (2016). Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst. Rev., 1.","DOI":"10.1002\/14651858.CD008891.pub3"},{"key":"ref_287","first-page":"8","article-title":"The Evolution of Methotrexate as a Treatment for Ectopic Pregnancy and Gestational Trophoblastic Neoplasia: A Review","volume":"2012","author":"Skubisz","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/bjc.2012.65","article-title":"Uterine artery pulsatility index: A predictor of methotrexate resistance in gestational trophoblastic neoplasia","volume":"106","author":"Agarwal","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"vi39","DOI":"10.1093\/annonc\/mdt345","article-title":"Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Seckl","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"5","DOI":"10.15761\/COGRM.1000103","article-title":"Management of gestational trophoblastic neoplasia","volume":"1","author":"Hussain","year":"2015","journal-title":"Clin. Obstet. Gynecol. Reprod. Med."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1590\/SO100-720320140005198","article-title":"Diagnosis, classification and treatment of gestational trophoblastic neoplasia","volume":"37","author":"Biscaro","year":"2015","journal-title":"Rev. Bras. Ginecol. Obstet."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdx211","article-title":"Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset","volume":"28","author":"Eysbouts","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_293","first-page":"892","article-title":"Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: Successful treatment with rituximab","volume":"60","author":"Stewart","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"ref_296","doi-asserted-by":"crossref","unstructured":"Jankowitz, R.C., Ganon, J., Blodgett, T., Garcia, C., and Jacobs, S. (2009). A Putative Case of Methotrexate-Related Lymphoma: Clinical Course and PET\/CT Findings. Case Rep Med, 2009.","DOI":"10.1155\/2009\/469343"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.24287","article-title":"Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies","volume":"125","author":"Anderson","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.2169\/internalmedicine.0875-18","article-title":"Methotrexate-associated Intravascular Large B-cell Lymphoma in a Patient with Rheumatoid Arthritis: A Very Rare Case","volume":"57","author":"Hagihara","year":"2018","journal-title":"Intern. Med."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/ard.56.2.97","article-title":"Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate","volume":"56","author":"Bolonga","year":"1997","journal-title":"Ann. Rheum. Dis."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1001\/jama.1977.03280250057025","article-title":"Hepatoma in a Child with Methotrexate-Induced Hepatic Fibrosis","volume":"238","author":"Ruymann","year":"1977","journal-title":"JAMA"},{"key":"ref_301","first-page":"43","article-title":"Methotrexate-induced acute leukemia: Report of three cases and review of the literature","volume":"2","author":"Eltayeb","year":"2009","journal-title":"Clin. Med. Case Rep."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00415-016-8359-x","article-title":"An update on treatments in myasthenia gravis","volume":"264","author":"Jones","year":"2017","journal-title":"J. Neurol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/10\/3483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:28:57Z","timestamp":1760174937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/10\/3483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":302,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijms21103483"],"URL":"https:\/\/doi.org\/10.3390\/ijms21103483","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]}}}